The webcast event will be hosted by Molecure on the
The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure's pipeline programs.
Agenda topics: 13.30-15.30
Molecure's Vision, Strategy and Pipeline
OATD-01, Molecure's first in class chitinase inhibitor: Clinical evaluation in sarcoidosis and potential patient impact (
Landscape and therapy opportunity in sarcoidosis
Clinical development plan
Other opportunities in interstitial lung disease
OATD-02, Molecure's novel dual arginase inhibitor: o Pre-clinical activity in a broad range of cancers o State of oncology in
Clinical development plan 15.30-15.40 Break 15.40-16.30
Early-stage pipeline
Deubiquitinating enzymes (DUBs) program including USP7 in oncology
YKL40 in oncology
mRNA platform
Key Opinion Leader Presenters:
Cezary Szczylik, Oncologist, Head of the
Dr Zbigniew Zasona - VP Research Biology, Member of the Board
Dr
Dr Nicolas Beuzen - Director of Business Development and Licensing
Contact:
Tel: +(48) 728 728 143
Email: m.borkowska@molecure.com
About Molecure
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of underexplored protein and RNA targets to treat multiple incurable diseases.
Molecure has generated a diverse pipeline of eight distinct programs with the support of leading academic life science institutions globally, including
Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
Molecure's headquarters and laboratories are located in
(C) 2022 Electronic News Publishing, source